Agile Therapeutics, Inc.
AGRX
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 32.21% | 66.15% | 79.99% | 137.70% | 143.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.21% | 66.15% | 79.99% | 137.70% | 143.93% |
| Cost of Revenue | 6.17% | 18.37% | 31.33% | -22.45% | -39.29% |
| Gross Profit | 53.75% | 128.27% | 162.14% | 564.89% | 262.82% |
| SG&A Expenses | -21.86% | -24.32% | -33.05% | -36.37% | -39.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.57% | -17.75% | -24.55% | -34.65% | -40.64% |
| Operating Income | 48.46% | 51.07% | 52.01% | 60.09% | 59.61% |
| Income Before Tax | 16.80% | 61.83% | 51.92% | 69.51% | 66.28% |
| Income Tax Expenses | -- | -- | -- | 100.00% | 100.00% |
| Earnings from Continuing Operations | 16.80% | 61.83% | 43.07% | 66.04% | 63.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.80% | 61.83% | 43.07% | 66.04% | 63.24% |
| EBIT | 48.46% | 51.07% | 52.01% | 60.09% | 59.61% |
| EBITDA | 48.94% | 50.72% | 51.13% | 59.31% | 58.98% |
| EPS Basic | 84.49% | 95.19% | 95.84% | 97.67% | 97.72% |
| Normalized Basic EPS | 44.37% | 94.01% | 96.68% | 97.90% | 99.41% |
| EPS Diluted | 84.48% | 95.19% | 95.84% | 97.67% | 97.72% |
| Normalized Diluted EPS | 44.37% | 94.01% | 96.68% | 97.90% | 99.41% |
| Average Basic Shares Outstanding | 309.79% | 379.78% | 400.56% | 578.57% | 1,543.38% |
| Average Diluted Shares Outstanding | 309.79% | 379.78% | 400.56% | 578.57% | 1,543.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
